Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Ann

Name	Symbol	Market	Type
Saint Gobain Bonds Stgobaintp83t1	EU:SGP	Euronext	Bond

Name

Symbol

Market

Type

Saint Gobain Bonds Stgobaintp83t1

EU:SGP

Euronext

Bond

	Price Change	% Change	Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Traded	Last Trade
	0.00	0.00%	120.00	114.00	120.00				0	01:00:00

Price Change

% Change

Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Traded

Last Trade

0.00

0.00%

120.00

114.00

120.00

01:00:00

Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Ann

01/11/2009 10:00pm

PR Newswire (US)

Saint Gobain Bonds Stgob... (EU:SGP)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more Saint Gobain Bonds Stgob... Charts.

BOSTON, Nov. 1 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE:SGP) today reported two data presentations supporting response guided therapy with boceprevir combination therapy in patients with chronic hepatitis C virus (HCV) genotype 1. These retrospective analyses were presented at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3. Boceprevir is an investigational HCV protease inhibitor. Phase III registration studies with boceprevir in treatment-naïve HCV patients and patients who failed prior treatment have been fully enrolled and are expected to be completed in mid-2010. Boceprevir response guided therapy utilizes a unique 4-week lead-in of PEGINTRON(R) (peginterferon alfa-2b) and REBETOL(R) (ribavirin, USP) prior to the addition of boceprevir (800 mg TID) for an additional 24-44 weeks. Response guided therapy is intended to enable the physician to determine the duration of boceprevir combination therapy based on a patient's viral response during treatment. Although baseline characteristics cannot predict which patients may benefit from longer therapy, in-treatment virologic responses appear likely to do so. The lead-in strategy allows for an assessment to define a patient's response to peginterferon and ribavirin alone in this initial 4-week treatment period. Boceprevir Response Guided Therapy in Null Responder Patients The boceprevir Phase II HCV SPRINT-1 study in treatment-naïve patients with HCV genotype 1 had two treatment arms in which patients received a 4-week lead-in followed by the addition of boceprevir for an additional 24 or 44 weeks (n=206). In an oral presentation at AASLD,(1) researchers analyzed results from these two arms to determine SVR rates in patients who had a null response to peginterferon and ribavirin therapy (defined as

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

SGP Saint Gobain Bonds Stgobaintp83t1